Boehringer Ingelheim halts sale of new horse vaccine; Animal nutrition companies Alltech and Ridley merge;

> Boehringer Ingelheim's Vetmedica voluntarily halted sales of its conditionally licensed equine vaccine for Corynebacterium pseudotuberculosis bacterin-toxoid, commonly known as "pigeon fever," while it investigates reports of gastrointestinal side effects. Article

> Alltech, a maker of animal nutrition products, purchased Ridley for $521 million Canadian dollars ($428 million), giving the combined company a presence in 128 countries an annual revenues of $1.6 billion. Release

> VetCor Group Holdings, which operates 137 veterinary hospitals in 19 states, announced that it has completed a recapitalization led by private equity firms Harvest Partners and Cressey & Company. Release

> The USDA awarded $3 million in grants to researchers at Mississippi State University, Ohio State University and the University of Vermont, to fund projects aimed at minimizing the loss of livestock to insects and diseases. Release

> Health Canada announced it will strengthen regulations and propose new measures to encourage the proper use of antibiotics in food animals. Article

> TFH Publications/Nylabone Products recalled one lot of its Puppy Starter Kit dog chews due to potential Salmonella contamination. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…